SBIR/STTR Research Award

Antimicrobial Intravascular Catheter Lock Solutions Based on Endogenous Nitric Oxide Release Agent

Award identifier 7ecdea14549a7d0225abb8e2b19de950f0aeb60e936d1a773c048b51eb71aef5Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$233,275

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
NOTA Laboratories, Inc.
Proposal award date
2018-09-01
Contract end date
2019-08-31
UEI
XXXBEN625JK5
Solicitation number
PA16-302
Topic code
NIAID

Research abstract

! AbstractIntravascularIVcatheters in the hospital setting are associated with a high rate of bacterial colonizationresulting in andgtdeaths annually in the U Sfrom catheter related blood stream infectionsCR BSIsNewer commercial catheters pre loaded with silver or antibiotics within their walls have failed to dramatically reduce this very significant problemA variety of catheter lock solutionscatheters that are filled with these solutions when not in usecontaining antibioticsethanol and other antimicrobials are currently employed in hospitals around the worldHowever none of the antimicrobial agents used in existing lock solutions are able to diffuse through the walls of the catheters and prevent infection and biofilm formation on the outer surfaces of the cathetersFurthermicrobial biofilm commonly formed on catheter surfaces is particularly resistant to antibiotic treatment owing to the inability of the antibiotics to penetrate the protective polysaccharide matrix associated with biofilmNitric oxideNOis an endogenous antimicrobial agent that kills planktonic bacteria as well as those microbes within a biofilmRecent research has demonstrated that NO release from catheters surfaces using NO donors incorporated into the walls of the catheters is quite effective in preventing bacterial colonizationHoweverthe use of exogenous NO donors within the walls of catheters will likely face significant FDA hurdles associated with ensuring the safety of the specific NO donors utilizedTo move NO release catheters more quickly into clinical useNOTA plans to create a simple NO release IV catheter lock solution that will be reconstituted from a dry powder statein vialby hospital personnel immediately before useand then loaded into the IV catheter using a syringeThe solution will contain a proprietary mixture of S nitrosogutathioneGSNOa known carrier of NO within the human bodyalong with S glutathione and or ascorbatevitamin Cas accelerants to control the rate of NO release from GSNO over many hoursin physiological saline solutionPhase I will focus onoptimizing the GSNO additive formulation s NO release kinetics and examining dry state storage stability overmonths of different recipesdetermining the duration and magnitude of NO release for different concentrations of lock solution reagents when loaded within the lumen of catheters made of different polymeric materialsandassess the antimicrobial activity of different catheter tubing loaded with fresh GSNO additive lock solutionsreplaced dailyoverd periods against Saureus and Paeruginosa using a CDC bioreactor modelGiven the known presence of GSNO in bloodthe proposed use of antimicrobial GSNO based catheter lock solutions should be a very safeeffectiveand inexpensive new approach to greatly reduce the rates of CR BSIs NARRATIVE IntravascularIVcatheter associated bloodstream infections are a very major problem in the hospital settingcausing andgtdeaths annually in the U Saloneand also significantly increasing healthcare costsEfforts to develop silver and antibiotic impregnated catheters haveto datenot resolved the high infection rates associated with IV cathetersNOTA Laboratories now plans to develop a new product line of various dry reagent formulations containing S nitrosoglutathioneGSNOalong with appropriate additives in a saline backgroundthat can be reconstituted with pure water at the patient s bedside for use as completely new and much more effective antimicrobial lock solutions in the hospital settingThe NO gas generated within the lock solution from the GSNO confined within the lumen sof catheters will be capable of preventing bacterial colonization on both the inner and outer surfaces of the catheter owing to NO s ability to readily permeate the walls of the catheternot possible with antibioticsand serve as localized bactericidal agent and also prevent disperse microbial biofilm

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

8 SBIR/STTR records share this UEI (2015–2022). Reported award amounts total $5,860,484. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.